Cargando…

Effect of a mobile app chatbot and an interactive small-group webinar on COVID-19 vaccine intention and confidence in Japan: a randomised controlled trial

INTRODUCTION: We investigated the effect of social media-based interventions on COVID-19 vaccine intention (VI) and confidence in Japan. METHODS: We conducted a three-arm randomised controlled trial between 5 November 2021 and 9 January 2022 during a low incidence (<1000/day) of COVID-19 in Japan...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Takaaki, Tomoi, Hana, Nishina, Yuka, Harada, Ko, Tanaka, Kyuto, Sasaki, Shugo, Inaba, Kanako, Mitaka, Hayato, Takahashi, Hiromizu, Passanante, Aly, Lau, Eric H Y, Naito, Toshio, Larson, Heidi, Wu, Joseph, Lin, Leesa, Yamada, Yuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230336/
https://www.ncbi.nlm.nih.gov/pubmed/37247873
http://dx.doi.org/10.1136/bmjgh-2022-010370
_version_ 1785051506702024704
author Kobayashi, Takaaki
Tomoi, Hana
Nishina, Yuka
Harada, Ko
Tanaka, Kyuto
Sasaki, Shugo
Inaba, Kanako
Mitaka, Hayato
Takahashi, Hiromizu
Passanante, Aly
Lau, Eric H Y
Naito, Toshio
Larson, Heidi
Wu, Joseph
Lin, Leesa
Yamada, Yuji
author_facet Kobayashi, Takaaki
Tomoi, Hana
Nishina, Yuka
Harada, Ko
Tanaka, Kyuto
Sasaki, Shugo
Inaba, Kanako
Mitaka, Hayato
Takahashi, Hiromizu
Passanante, Aly
Lau, Eric H Y
Naito, Toshio
Larson, Heidi
Wu, Joseph
Lin, Leesa
Yamada, Yuji
author_sort Kobayashi, Takaaki
collection PubMed
description INTRODUCTION: We investigated the effect of social media-based interventions on COVID-19 vaccine intention (VI) and confidence in Japan. METHODS: We conducted a three-arm randomised controlled trial between 5 November 2021 and 9 January 2022 during a low incidence (<1000/day) of COVID-19 in Japan in the midst of the second and the third waves. Japanese citizens aged ≥20 who had not received any COVID-19 vaccine and did not intend to be vaccinated were randomly assigned to one of the following three groups: (1) a control group, (2) a group using a mobile app chatbot providing information on COVID-19 vaccines and (3) a group using interactive webinars with health professionals. VI and predefined Vaccine Confidence Index (VCI) measuring confidence in the importance, safety and effectiveness were compared before and after the interventions under intention-to-treat principle. Logistic regression models were used to investigate the effect of each intervention on postintervention VI and changes of VCI compared with control. RESULTS: Among 386 participants in each group, 359 (93.0%), 231 (59.8%) and 207 (53.6%) completed the postsurvey for the control, chatbot and webinar groups, respectively. The average duration between the intervention and the postsurvey was 32 days in chatbot group and 27 days in webinar group. VI increased from 0% to 18.5% (95% CI 14.5%, 22.5%) in control group, 15.4% (95% CI 10.8%, 20.1%) in chatbot group and 19.7% (95% CI 14.5%, 24.9%) in webinar group without significant difference (OR for improvement=0.8 (95% CI 0.5, 1.3), p=0.33 between chatbot and control, OR=1.1 (95% CI 0.7, 1.6), p=0.73 between webinar and control). VCI change tended to be larger in chatbot group compared with control group without significant difference (3.3% vs −2.5% in importance, OR for improvement=1.3 (95% CI 0.9, 2.0), p=0.18; 2.5% vs 1.9% in safety, OR=1.1 (95% CI 0.7, 1.9), p=0.62; −2.4% vs −7.6% in effectiveness, OR=1.4 (95% CI 0.9, 2.1), p=0.09). Improvement in VCI was larger in webinar group compared with control group for importance (7.8% vs −2.5%, OR=1.8 (95% CI 1.2, 2.8), p<0.01), effectiveness (6.4% vs −7.6%, OR=2.2 (95% CI 1.4, 3.4), p<0.01) and safety (6.0% vs 1.9%, OR=1.6 (95% CI 1.0, 2.6), p=0.08). CONCLUSION: This study demonstrated that neither the chatbot nor the webinar changed VI importantly compared with control. Interactive webinars could be an effective tool to change vaccine confidence. Further study is needed to identify risk factors associated with decreased vaccine confidence and investigate what intervention can increase VI and vaccine confidence for COVID-19 vaccines. TRIAL REGISTRATION NUMBER: UMIN000045747.
format Online
Article
Text
id pubmed-10230336
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-102303362023-06-01 Effect of a mobile app chatbot and an interactive small-group webinar on COVID-19 vaccine intention and confidence in Japan: a randomised controlled trial Kobayashi, Takaaki Tomoi, Hana Nishina, Yuka Harada, Ko Tanaka, Kyuto Sasaki, Shugo Inaba, Kanako Mitaka, Hayato Takahashi, Hiromizu Passanante, Aly Lau, Eric H Y Naito, Toshio Larson, Heidi Wu, Joseph Lin, Leesa Yamada, Yuji BMJ Glob Health Original Research INTRODUCTION: We investigated the effect of social media-based interventions on COVID-19 vaccine intention (VI) and confidence in Japan. METHODS: We conducted a three-arm randomised controlled trial between 5 November 2021 and 9 January 2022 during a low incidence (<1000/day) of COVID-19 in Japan in the midst of the second and the third waves. Japanese citizens aged ≥20 who had not received any COVID-19 vaccine and did not intend to be vaccinated were randomly assigned to one of the following three groups: (1) a control group, (2) a group using a mobile app chatbot providing information on COVID-19 vaccines and (3) a group using interactive webinars with health professionals. VI and predefined Vaccine Confidence Index (VCI) measuring confidence in the importance, safety and effectiveness were compared before and after the interventions under intention-to-treat principle. Logistic regression models were used to investigate the effect of each intervention on postintervention VI and changes of VCI compared with control. RESULTS: Among 386 participants in each group, 359 (93.0%), 231 (59.8%) and 207 (53.6%) completed the postsurvey for the control, chatbot and webinar groups, respectively. The average duration between the intervention and the postsurvey was 32 days in chatbot group and 27 days in webinar group. VI increased from 0% to 18.5% (95% CI 14.5%, 22.5%) in control group, 15.4% (95% CI 10.8%, 20.1%) in chatbot group and 19.7% (95% CI 14.5%, 24.9%) in webinar group without significant difference (OR for improvement=0.8 (95% CI 0.5, 1.3), p=0.33 between chatbot and control, OR=1.1 (95% CI 0.7, 1.6), p=0.73 between webinar and control). VCI change tended to be larger in chatbot group compared with control group without significant difference (3.3% vs −2.5% in importance, OR for improvement=1.3 (95% CI 0.9, 2.0), p=0.18; 2.5% vs 1.9% in safety, OR=1.1 (95% CI 0.7, 1.9), p=0.62; −2.4% vs −7.6% in effectiveness, OR=1.4 (95% CI 0.9, 2.1), p=0.09). Improvement in VCI was larger in webinar group compared with control group for importance (7.8% vs −2.5%, OR=1.8 (95% CI 1.2, 2.8), p<0.01), effectiveness (6.4% vs −7.6%, OR=2.2 (95% CI 1.4, 3.4), p<0.01) and safety (6.0% vs 1.9%, OR=1.6 (95% CI 1.0, 2.6), p=0.08). CONCLUSION: This study demonstrated that neither the chatbot nor the webinar changed VI importantly compared with control. Interactive webinars could be an effective tool to change vaccine confidence. Further study is needed to identify risk factors associated with decreased vaccine confidence and investigate what intervention can increase VI and vaccine confidence for COVID-19 vaccines. TRIAL REGISTRATION NUMBER: UMIN000045747. BMJ Publishing Group 2023-05-29 /pmc/articles/PMC10230336/ /pubmed/37247873 http://dx.doi.org/10.1136/bmjgh-2022-010370 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Kobayashi, Takaaki
Tomoi, Hana
Nishina, Yuka
Harada, Ko
Tanaka, Kyuto
Sasaki, Shugo
Inaba, Kanako
Mitaka, Hayato
Takahashi, Hiromizu
Passanante, Aly
Lau, Eric H Y
Naito, Toshio
Larson, Heidi
Wu, Joseph
Lin, Leesa
Yamada, Yuji
Effect of a mobile app chatbot and an interactive small-group webinar on COVID-19 vaccine intention and confidence in Japan: a randomised controlled trial
title Effect of a mobile app chatbot and an interactive small-group webinar on COVID-19 vaccine intention and confidence in Japan: a randomised controlled trial
title_full Effect of a mobile app chatbot and an interactive small-group webinar on COVID-19 vaccine intention and confidence in Japan: a randomised controlled trial
title_fullStr Effect of a mobile app chatbot and an interactive small-group webinar on COVID-19 vaccine intention and confidence in Japan: a randomised controlled trial
title_full_unstemmed Effect of a mobile app chatbot and an interactive small-group webinar on COVID-19 vaccine intention and confidence in Japan: a randomised controlled trial
title_short Effect of a mobile app chatbot and an interactive small-group webinar on COVID-19 vaccine intention and confidence in Japan: a randomised controlled trial
title_sort effect of a mobile app chatbot and an interactive small-group webinar on covid-19 vaccine intention and confidence in japan: a randomised controlled trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230336/
https://www.ncbi.nlm.nih.gov/pubmed/37247873
http://dx.doi.org/10.1136/bmjgh-2022-010370
work_keys_str_mv AT kobayashitakaaki effectofamobileappchatbotandaninteractivesmallgroupwebinaroncovid19vaccineintentionandconfidenceinjapanarandomisedcontrolledtrial
AT tomoihana effectofamobileappchatbotandaninteractivesmallgroupwebinaroncovid19vaccineintentionandconfidenceinjapanarandomisedcontrolledtrial
AT nishinayuka effectofamobileappchatbotandaninteractivesmallgroupwebinaroncovid19vaccineintentionandconfidenceinjapanarandomisedcontrolledtrial
AT haradako effectofamobileappchatbotandaninteractivesmallgroupwebinaroncovid19vaccineintentionandconfidenceinjapanarandomisedcontrolledtrial
AT tanakakyuto effectofamobileappchatbotandaninteractivesmallgroupwebinaroncovid19vaccineintentionandconfidenceinjapanarandomisedcontrolledtrial
AT sasakishugo effectofamobileappchatbotandaninteractivesmallgroupwebinaroncovid19vaccineintentionandconfidenceinjapanarandomisedcontrolledtrial
AT inabakanako effectofamobileappchatbotandaninteractivesmallgroupwebinaroncovid19vaccineintentionandconfidenceinjapanarandomisedcontrolledtrial
AT mitakahayato effectofamobileappchatbotandaninteractivesmallgroupwebinaroncovid19vaccineintentionandconfidenceinjapanarandomisedcontrolledtrial
AT takahashihiromizu effectofamobileappchatbotandaninteractivesmallgroupwebinaroncovid19vaccineintentionandconfidenceinjapanarandomisedcontrolledtrial
AT passanantealy effectofamobileappchatbotandaninteractivesmallgroupwebinaroncovid19vaccineintentionandconfidenceinjapanarandomisedcontrolledtrial
AT lauerichy effectofamobileappchatbotandaninteractivesmallgroupwebinaroncovid19vaccineintentionandconfidenceinjapanarandomisedcontrolledtrial
AT naitotoshio effectofamobileappchatbotandaninteractivesmallgroupwebinaroncovid19vaccineintentionandconfidenceinjapanarandomisedcontrolledtrial
AT larsonheidi effectofamobileappchatbotandaninteractivesmallgroupwebinaroncovid19vaccineintentionandconfidenceinjapanarandomisedcontrolledtrial
AT wujoseph effectofamobileappchatbotandaninteractivesmallgroupwebinaroncovid19vaccineintentionandconfidenceinjapanarandomisedcontrolledtrial
AT linleesa effectofamobileappchatbotandaninteractivesmallgroupwebinaroncovid19vaccineintentionandconfidenceinjapanarandomisedcontrolledtrial
AT yamadayuji effectofamobileappchatbotandaninteractivesmallgroupwebinaroncovid19vaccineintentionandconfidenceinjapanarandomisedcontrolledtrial